Top

Journal of Cardiovascular Translational Research

Published in:

01-03-2009

The Biological Basis of Thrombosis and Bleeding in Patients with Ventricular Assist Devices

Authors: Ranjit John, Sangjin Lee

Published in: Journal of Cardiovascular Translational Research | Issue 1/2009

Abstract

The clinical success of left ventricular assist devices (LVADs) has been tempered by significant hemorrhagic and thromboembolic complications. In the case of LVADs, where the biomaterial is in direct contact with the blood circulation, significant changes in systemic immunologic and thrombostatic functions have been well documented. Although further investigation is warranted, significant advances have been made in both cellular biology and LVAD technology to better understand the delicate balance between the procoagulant milieu predisposing to thrombosis and the risks of both surgical and non-surgical bleeding.

Frazier, O. H., Rose, E. A., Oz, M. C., Dembitsky, W., McCarthy, P., Radovancevic, B., et al. (2001). Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. Journal of Thoracic and Cardiovascular Surgery, 122, 1186–1195.PubMedCrossRef

Goldstein, D. J., Oz, M. C., & Rose, E. A. (1998). Implantable left ventricular assist devices. New England Journal of Medicine, 339, 1522–1533.PubMedCrossRef

Rose, E. A., Gelijns, A., Moskowitz, A. J., et al. (2001). Long-term mechanical left ventricular assistance for end-stage heart failure. New England Journal of Medicine, 345, 1435–1443.PubMedCrossRef

McCarthy, P. M., Smedira, N. O., Vargo, R. L., et al. (1998). One hundred patients with the Heartmate left ventricular assist device: Evolving concepts and technology. Journal of Thoracic and Cardiovascular Surgery, 115, 904–912.PubMedCrossRef

Morgan, J., John, R., Rao, V., et al. (2004). Bridging to transplant with the Heartmate left ventricular assist device: The Columbia Presbyterian twelve-year experience. Journal of Thoracic and Cardiovascular Surgery, 127, 1309–1316.PubMedCrossRef

Kasirajan, V., McCarthy, P. M., Hoercher, K. J., et al. (2000). Clinical experience with long-term use of implantable left ventricular assist devices: Indications, implantation and outcomes. Seminars in Thoracic and Cardiovascular Surgery, 12, 229–237.PubMed

Tsukui, H., Abla, A., Teuteberg, J. J., McNamara, D. M., Mathier, M. A., Cadaret, L. M., et al. (2007). Cerebrovascular accidents in patients with a ventricular assist device. Journal of Thoracic and Cardiovascular Surgery, 134, 114–123.PubMedCrossRef

Goldstein, D. J., & Beauford, R. B. (2003). Left ventricular assist devices and bleeding: Adding insult to injury. Annals of Thoracic Surgery, 75, S42–S47.PubMedCrossRef

Lazar, R. M., Shapiro, P. A., Jaski, B. E., Parides, M. K., Bourge, R. C., Watson, J. T., et al. (2004). Neurological events during long-term mechanical circulatory support for heart failure: The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (RMATCH)experience. Circulation, 109, 2424–2427.

10.

John, R., Kamdar, F., Liao, K., et al. (2008). Low thromboembolic risk with the HeartMate II left ventricular assist device. Journal of Thoracic and Cardiovascular Surgery (in press)

11.

Delgado, R., Frazier, O. H., Myers, T. J., et al. (2005). Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device. Journal of Heart and Lung Transplantation, 24, 231–233.PubMedCrossRef

12.

Griffith, B. P., Kormos, R. L., Borovetz, H. S., et al. (2001). HeartMate II left ventricular assist system: From concept to first clinical use. Annals of Thoracic Surgery, 71, 116–120.CrossRef

13.

Rose, E. A., Levin, H. R., Oz, M. C., et al. (1994). Artificial circulatory support with textured interior surfaces: A counterintuitive approach to minimize thromboembolism. Circulation, 90(5 pt 2), II87–II91.PubMed

14.

Esmore, D., Kaye, D., Spratt, P., et al. (2008). A prospective, multicenter trial of the VentrAssist left ventricular assist device for bridge to transplant: Safety and efficacy. Journal of Heart and Lung Transplantation, 27, 579–588.PubMedCrossRef

15.

Frazier, O. H., Myers, T. J., Westaby, S., et al. (2003). Use of the Jarvik 2000 left ventricular assist system as a bridge to heart transplantation or as destination therapy for patients with chronic heart failure. Annals of Surgery, 237, 631–637.PubMedCrossRef

16.

Westaby, S., Katsumata, T., Houel, R., et al. (1998). Jarvik 2000 heart: Potential for bridge to myocyte recovery. Circulation, 98, 1568–1574.PubMed

17.

Frazier, O. H., Myers, T. J., Westaby, S., & Gregoric, I. D. (2004). Clinical experience with an implantable, intracardiac, continuous flow circulatory support device: Physiologic implications and their relationship to patient selection. Annals of Thoracic Surgery, 77(1), 133–142.PubMedCrossRef

18.

Haj-Yahia, S., Birks, E., Rogers, P., et al. (2007). Midterm reliability with the Jarvik 2000 axial flow left ventricular assist device. Journal of Thoracic and Cardiovascular Surgery, 134, 199–203.PubMedCrossRef

19.

Clark, R. E., Brillman, J., Davis, D. A., Lovell, M. R., Price, T. R., & Magovern, G. J. (1995). Microemboli during coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 109, 249–258.PubMedCrossRef

20.

Georgiadis, D., Grosset, D. G., Kelman, A., Faichney, A., & Lees, K. R. (1994). Prevalence and characteristics of intercranial microembolic signals in patients with different types of prosthetic cardiac valves. Stroke, 25, 587–592.PubMed

21.

Schmid, C., Weyand, M., Nabavi, D. G., Hammel, D., Deng, M. C., Ringelstein, E. B., et al. (1998). Cerebral and systemic embolization during left ventricular support with the Novacor N100 device. Annals of Thoracic Surgery, 65, 1703–1710.PubMedCrossRef

22.

Thoennissen, N. H., Schneider, M., Allroggen, A., Ritter, M., Dittrich, R., Schmis, C., et al. (2005). High level of cerebral microembolization in patients supported with the DeBakey left ventricular assist device. Journal of Thoracic and Cardiovascular Surgery, 130, 1159–1166.PubMedCrossRef

23.

Moazami, N., Roberts, K., Argenziano, M., Catanese, K., Mohr, J. P., Rose, E. A., et al. (1997). Asymptomatic microembolism in patients with long-term ventricular assist support. ASAIO Journal, 43, 177–180.PubMedCrossRef

24.

Nabavi, D. G., Stockmann, J., Schmid, C., Schneider, M., Hammel, D., Scheld, H. H., et al. (2003). Doppler microemboli load predicts risk of thromboembolic complications in Novacor patients. Journal of Thoracic and Cardiovascular Surgery, 126, 160–167.PubMedCrossRef

25.

Wilhelm, C. R., Ristich, J., Knepper, L. E., Holubkov, R., Wisniewski, S. R., Kormos, R. L., et al. (1999). Measurement of hemostatic indexes in conjunction with transcranial Doppler sonography in patients with ventricular assist devices. Stroke, 30, 2554–2561.PubMed

26.

Spanier, T. B., Oz, M. C., Levin, H. R., Weinberg, A., Stomatis, K., Stern, D., et al. (1996). Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. Journal of Thoracic and Cardiovascular Surgery, 112, 1090–1097.PubMedCrossRef

27.

Spanier, T. B., Chen, J. M., Oz, M. C., Stern, D. M., Rose, E. A., & Schmidt, A. M. (1999). Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant response. Journal of Thoracic and Cardiovascular Surgery, 118, 404–413.PubMedCrossRef

28.

Hampton, C. R., & Verrier, E. D. (2002). Systemic consequences of ventricular assist devices: Alterations of coagulation, immune function, inflammation, and the neuroendocrine system. Artificial Organs, 26, 902–908.PubMedCrossRef

29.

Livingston, E. R., Fisher, C. A., Bibidakis, E. J., Pathak, A. S., Todd, B. A., Furkawa, S., et al. (1996). Increased activation of the coagulation and fibrinolytic pathways leads to hemorrhagic complications during left ventricular assist implantation. Circulation, 94, II227–II234.PubMed

30.

Koster, A., Loebe, M., Hansen, R., Potapov, E. V., Noon, G. P., Kuppe, H., et al. (2000). Alterations in coagulation after implantation of a pulsatile Novacor LVAD and the axial flow MicroMed DeBakey LVAD. Annals of Thoracic Surgery, 70, 533–537.PubMedCrossRef

31.

Himmelreich, G., Ullmann, H., Riess, H., Rosch, R., Loebe, M., Schiessler, A., et al. (1995). Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device. ASAIO Journal, 41, M790–M794.PubMedCrossRef

32.

Panch, S., Hrabe, J., Solovey, A., Joyce, L., Hebbel, R., & John, R. (2007). Activation of the endothelial and coagulation systems in left ventricular assist device (LVAD) recipients. Circulation, 116, II643–II644.

33.

Panch, S. R., Hrabe, J., Solovey, A., Toninato, C., Hebbel, R. P., & John, R. (2008). Sustained activation of vascular endothelium induces the tissue factor pathway in LVAD recipients. Journal of Heart and Lung Transplantation, 27, S93.CrossRef

34.

Hebbel, R. P. (1997). Adhesive interactions of sickle erythrocytes with endothelium. Journal of Clinical Investigation, 99, 2561–2564.PubMedCrossRef

35.

Solovey, A., Gui, L., & Hebbel, R. P. (1997). Circulating activated endothelial cells in sickle cell anemia. New England Journal of Medicine, 337, 1584.PubMedCrossRef

36.

Solovey, A., Gui, L., Key, N., & Hebbel, R. P. (1998). Tissue factor expression by endothelial cells in sickle cell anemia. Journal of Clinical Investigation, 101, 1899.PubMedCrossRef

37.

Wilhelm, C. R., Ristich, J., Kormos, R. L., & Wagner, W. R. (1998). Monocyte tissue factor expression and ongoing complement generation in ventricular assist device patients. Annals of Thoracic Surgery, 65, 1071–1076.PubMedCrossRef

38.

Menconi, M. J., Prockwinse, S., Owen, T. A., Dasse, K. A., Stein, G. S., & Lian, G. B. (1995). Properties of blood-contacting surfaces of clinically implanted cardiac assist devices: Gene expression, matrix composition, and ultra structural characterization of cellular linings. Journal of Cellular Biochemistry, 57, 557–573.PubMedCrossRef

39.

Frazier, O. H., Baldwin, R. T., Eskin, S. G., & Duncan, J. M. (1993). Immunochemical identification of human endothelial cells on the lining of a ventricular assist device. Texas Heart Institute Journal, 20, 78–82.PubMed

40.

Kavarana, M. N., Pessin-Minsley, M. S., Urtecho, J., et al. (2002). Right ventricular dysfunction and organ failure in left-ventricular assist device recipients: A continuing problem. Annals of Thoracic Surgery, 73, 745–750.PubMedCrossRef

41.

Korfer, R., El-Banayosy, A., Arusoglu, L., et al. (2000). Single center experience with the Thoratec ventricular assist device. Journal of Thoracic and Cardiovascular Surgery, 119, 596–600.PubMedCrossRef

42.

Grossi, P., Dalla Gasperina, D., Pagani, F., et al. (2001). Infectious complications in patients with the Novacor left ventricular assist system. Transplantation Proceedings, 33, 1969–1971.PubMedCrossRef

43.

Itescu, S., & John, R. (2003). Interactions between the recipient immune system and the left ventricular assist device surface: Immunological and clinical implications. Annals of Thoracic Surgery, 75, S58–S65.PubMedCrossRef

44.

John, R., Lietz, K., Naka, Y., et al. (2003). Immunologic sensitization in recipients of left ventricular assist devices. Journal of Thoracic and Cardiovascular Surgery, 125, 578–591.PubMedCrossRef

45.

Goldstein, D. J., Seldomridge, J. A., Chen, J. M., et al. (1995). Use of aprotinin in LVAD recipients reduces blood loss, blood use and perioperative mortality. Annals of Thoracic Surgery, 59, 1063–1068.PubMedCrossRef

46.

John, R., Rajasinghe, H. A., Chen, J. M., et al. (2000). Impact of current management practices on early and late mortality in over 500 consecutive heart transplant recipients. Annals of Surgery, 232, 302–311.PubMedCrossRef

47.

Letsou, G. V., Shah, N., Gregoric, I. D., et al. (2005). Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. Journal of Heart and Lung Transplantation, 24, 105–109.PubMedCrossRef

48.

John, R., Kamdar, F., Liao, K., et al. (2008). Improved survival and decreasing incidence of adverse events using the HeartMate II left ventricular assist device as a bridge-to-transplant. Annals of Thoracic Surgery, 86, 1227–1234.

49.

Heyde, E. C. (1958). Gastrointestinal bleeding in aortic stenosis (letter). New England Journal of Medicine, 259, 196.

50.

Boley, S. J., Sammarteno, R., Adams, A., et al. (1977). On the nature and etiology of vascular ectasias of the colon. Degenerative lesions of aging. Gastroenterology, 72, 650–660.PubMed

51.

Warkentin, T. E., Moore, J. C., & Morgan, D. G. (1992). Aortic stenosis and bleeding gastrointestinal angiodysplasia: Is acquired von Willebrand’s disease the link? Lancet, 340, 35–37.PubMedCrossRef

52.

Furlan, M. (1996). von Willebrand factor: Molecular size and functional activity. Annals of Hematology, 72, 341–348.PubMedCrossRef

53.

Ruggeri, Z. M. (2003). von Willebrand factor. Current Opinion in Hematology, 10, 142–149.PubMedCrossRef

54.

Vincentelli, A., Susen, S., Le Tourneau, T., Six, I., Fabre, O., Juthier, F., et al. (2003). Acquired von Willebrand syndrome in aortic stenosis. New England Journal of Medicine, 349, 343–349.PubMedCrossRef

55.

Geisen, U., Heilmann, C., Beyersdorf, F., et al. (2008). Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. European Journal of Cardio-thoracic Surgery, 22, 679–684.CrossRef

56.

Joyce, L., John, R., Liao, K., Toninato, C., Colvin-Adams, M., Missov, E., et al. (2007). Will continuous flow left ventricular assist devices result in a higher incidence of gastrointestinal bleeding than pulsatile devices. ASAIO Journal, 53, 50A.CrossRef

Title: The Biological Basis of Thrombosis and Bleeding in Patients with Ventricular Assist Devices
Authors: Ranjit John
Sangjin Lee
Publication date: 01-03-2009
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 1/2009
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-008-9072-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Biological Basis of Thrombosis and Bleeding in Patients with Ventricular Assist Devices

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

MicroRNAs Challenge the Status Quo of Therapeutic Targeting

Panoramic View of The Fifth International Symposium on Stem Cell Therapy and Applied Cardiovascular Biotechnology, April 2008, Madrid (Spain)

Peri-infarct Pacing with CRT in the Early Postinfarct Phase to Attenuate Long-term Remodeling

Vulnerable Plaque Imaging—Current Techniques

Determinants of Delayed Preconditioning Against Myocardial Stunning in Chronically Instrumented Pigs

Endoventricular Electromechanical Mapping—The Diagnostic and Therapeutic Utility of the NOGA® XP Cardiac Navigation System

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page